Krsnaa Diagnostics (KRSNAA) investor relations material

Executive summary

• Achieved 22% year-over-year revenue growth in Q1 FY27, reaching INR 2,355 million, with strong expansion in both radiology and pathology segments.

• Retail revenue surged 64% YoY, driven by higher patient engagement, expanded reach, and deeper market penetration.

• Served 5.1 million patients and performed 16.1 million tests in Q1 FY27, reflecting a 2% YoY increase in both metrics.

• Approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, and scheduled the 16th AGM for September 28, 2026.

• Recommended a final dividend of INR 2.00 per share for FY 2024-25, with record date set for September 18, 2026.

Financial highlights

• Consolidated revenue from operations for Q1 FY27 was INR 2,355.32 million, up from INR 1,929.78 million in Q1 FY26.

• EBITDA rose 12% YoY to INR 588 million, but EBITDA margin declined by 221 bps to 25% due to upfront fixed costs for new labs and logistics.

• PAT decreased 19% YoY to INR 166 million, with PAT margin dropping 360 bps to 7%.

• Total expenses increased to INR 1,767 million (75% of revenue), with notable rises in fees to hospitals and other expenses.

• Standalone revenue for Q1 FY27 was INR 2,106.61 million, up from INR 1,756.15 million in Q1 FY26.

Outlook and guidance

• Continued focus on expanding retail and PPP-based diagnostic services, leveraging scale and technology for sustainable growth.

• Long-term business outlook remains positive, supported by policy tailwinds, cost leadership, and robust IT infrastructure.

• Management expects no material impact from ongoing tax proceedings on the financial position or performance for the quarter ended June 30, 2026.